Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.7k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #410

    Ser trods alt ikke ud til at det bliver det blodbad der var lag op til i åbning.

    1 Reply Last reply
    0
    • A Offline
      A Offline
      AaBforever
      wrote on sidst redigeret af
      #411

      US er gået i minus

      1 Reply Last reply
      0
      • A Offline
        A Offline
        AaBforever
        wrote on sidst redigeret af
        #412

        DAX nede 2%

        1 Reply Last reply
        0
        • A Offline
          A Offline
          AaBforever
          wrote on sidst redigeret af
          #413

          Mht. til shorterne er det fantastisk at se som Pandora er blevet revet rundt den sidste time. Algoritmerne er kommet på overarbejde 🙂

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bibob
            wrote on sidst redigeret af
            #414

            Jeg synes nu også at Genmab har haft elevatortjeneste den sidste time.

            1 Reply Last reply
            0
            • A Offline
              A Offline
              AaBforever
              wrote on sidst redigeret af
              #415

              Rolig bibob...den kommer ned i 1000...i dag 🙂

              1 Reply Last reply
              0
              • A Offline
                A Offline
                AaBforever
                wrote on sidst redigeret af
                #416

                Men spændende hvordan US ender ud i aften.

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #417

                  luk i 1046

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #418

                    God morgen. 🙂

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #419

                      Fra SA årsregnskab

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #420

                        Tisotumab Vedotin Program Highlights

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #421

                          Planned Pivotal Trial: Seattle Genetics and Genmab plan to advance tisotumab vedotin into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and could support registration under the FDA’s accelerated approval regulations. The trial is expected to begin in the first half of 2018.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #422

                            Expanding Clinical Development Program: Seattle Genetics and Genmab plan to initiate in 2018 a phase 2 trial of tisotumab vedotin as part of a combination regimen in women with first-line metastatic cervical cancer. In addition, a phase 2 trial is expected to begin in 2018 to evaluate tisotumab vedotin monotherapy in a range of other solid tumor types.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #423

                              Ikke nyt men bare en bekræftigelse

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #424

                                Tak for info Sukker. 🙂

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #425

                                  Udover deres BCMA ADC med GSK går de yderligere efter BCMA med denne:

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #426

                                    AACR Presence: Data from multiple research and early clinical abstracts will be featured at the American Association for Cancer Research (AACR) annual meeting being held April 14-18, 2018. Included will be preclinical data on SEA-BCMA, a novel empowered antibody using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology. SEA-BCMA is expected to advance into a phase 1 clinical trial for multiple myeloma during 2018.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #427

                                      SA er ude nogen tvivl det mest succesfulde ADC selskab, så godt det er her Genmabs satsede på ADC - det giver trods alt en stor tiltro 🙂

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #428

                                        tak Sukkeralf og god morgen

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #429

                                          Fidelity still likes Genmab https://www.reuters.com/article/europe-stocks/live-markets-fidelity-sees-value-in-european-drugmakers-tech-stocks-idUSL8N1PW6GT

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger